Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lung Neoplasms
Open-data reference.
24 US clinical trials · 9 currently recruiting
Active & Recent Trials
Real World Registry for Use of the Ion Endoluminal System
Intuitive Surgical
NCT06004440
Specimen Banking From Patients With Lung Cancer
University of Colorado, Denver
NCT01585675
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
Wake Forest University Health Sciences
NCT04577599
TELESCOPE- TELEhealth Shared Decision-making COaching
Rutgers, The State University of New Jersey
NCT05491213
Molecular Analysis of Oncogenes and Resistance Mechanisms in Lung Cancer
University of Colorado, Denver
NCT01580982
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
National Cancer Institute (NCI)
NCT06885697
TELEhealth Shared Decision-making COaching for Lung Cancer Screening in Primary Care (TELESCOPE) for Hispanics
Rutgers, The State University of New Jersey
NCT07165691
Circulating Tumor Cells (CTC) in Lung Cancer
Shadia Jalal
NCT02630615
Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM
Brown University
NCT06974604
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
Merck Sharp & Dohme
NCT04380636
A Phase I/II Study of Hypofractionated Proton Therapy for Stage II-III Non-Small Cell Lung Cancer
Proton Collaborative Group
NCT01770418
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
NCT06237881
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Merck Sharp & Dohme
NCT04738487
ELUCIDATE: Enabling Lung Cancer Identification Using Folate Receptor Targeting
On Target Laboratories
NCT04241315
Circulating Cytokines as Predictors of Radiation Induced Pulmonary Toxicity
University of Rochester
NCT00178230
Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)
Amgen
NCT00413283
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
NewLink Genetics Corporation
NCT00073398
Phase II Neoadjuvant Trial of a Continuous Infusion of Paclitaxel Plus Cisplatin Followed by Chest Radiotherapy for Patients With Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
NCT00001499
Study Evaluating MAC-321 in Non-small Cell Lung Cancer Refractory to Platinum-based Therapy
Wyeth is now a wholly owned subsidiary of Pfizer
NCT00063219
Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02897778
Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Syndax Pharmaceuticals
NCT02909452
Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer
Pharmacyclics
NCT00120939
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
University of California, San Diego
NCT01114958
Study of the Efficacy of an Investigational Drug in Adult Patients With Non Small-Cell Lung Cancer (NSCLC)
Pfizer
NCT00034957
Phase Distribution
| Phase | Trial count |
|---|---|
| Early Phase 1 | 8 |
| Phase 2 | 5 |
| Phase 3 | 3 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Reading the Lung Neoplasms Trial Landscape
ClinicalTrials.gov lists 24 US studies indexed under Lung Neoplasms, and 9 of those are currently open to recruitment — roughly 38% of the total volume on the registry. That ratio is a useful proxy for activity level: a high share of recruiting studies often signals that research interest is current and that new enrollment opportunities are appearing, while a low share typically means the field is dominated by completed or follow-up work where most participant spots have already been filled. These counts reflect the public registry only and include studies at every stage of design, so they should be read as an index of research attention rather than as a measure of treatment availability.
The phase distribution for Lung Neoplasms shows 3 late-stage studies (Phase 3 and Phase 4 combined) alongside 13 earlier-phase entries (Phase 1 through Phase 2). Phase 1 and Phase 2 studies focus on early safety signals, dosing, and preliminary effect, while Phase 3 studies are typically the larger efficacy and safety trials submitted toward regulatory review, and Phase 4 studies follow approved interventions in real-world use. A condition weighted toward later phases often reflects a mature research pipeline with several interventions already close to or past approval, whereas a heavier early-phase tilt suggests the field is still exploring new mechanisms and candidate approaches.
Top sponsor activity for Lung Neoplasms is led by Syndax Pharmaceuticals with 2 indexed trials, alongside 9 other organizations in the top contributor list. The list on this page surfaces up to 24 of the most relevant recent and active entries, ordered with recruiting studies first so practical options are visible. All figures are derived from the public ClinicalTrials.gov dataset maintained by the National Library of Medicine and are reproduced here for reference. Inclusion of a trial, sponsor, or intervention on this page is neither an endorsement nor a recommendation — eligibility, protocol changes, and site-level status can shift frequently, so always verify current details on ClinicalTrials.gov and consult a qualified healthcare provider before acting on anything you see here.
Frequently Asked Questions
How many clinical trials are there for Lung Neoplasms?
PlainTrial tracks 24 US clinical trials for Lung Neoplasms, of which 9 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Lung Neoplasms?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology — how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2024 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.